Phase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumors.
Helene Senellart
No relevant relationships to disclose
Jaafar Bennouna
Consultant or Advisory Role - Amgen
Honoraria - Boehringer Ingelheim; Roche
Nicolas Isambert
No relevant relationships to disclose
Helene De-Montserrat
No relevant relationships to disclose
Patrick J. Squiban
Employment or Leadership Position - Boehringer Ingelheim
Inga Tschoepe
Employment or Leadership Position - Boehringer Ingelheim
Jean-Pierre Delord
No relevant relationships to disclose